Strug­gling Ova­Science re­or­ga­nizes, stock plunges; Chugai inks €130M deal; Iron­wood, Al­ler­gan re­port new lina­clotide CR2 da­ta

• With its fer­til­i­ty game plan strug­gling, Waltham, MA-based Ova­Science says it will chop out 30% of its staff to help re­duce ex­pens­es and ex­tend its cash run­way. New CEO Har­ald Stock and COO Paul Chap­man are out the door as well, sig­nal­ing the kind of tur­moil that in­vestors hate. The com­pa­ny’s stock $OVAS plunged 29% this morn­ing as found­ing CEO Michelle Dipp stepped back in to over­see the com­pa­ny as it re­or­ga­nized and looked for a new CEO.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.